Targeted retinoblastoma management

Shields, Carol L.; Lally, Sara E.; Leahey, Ann; Jabbour, Pascal; Caywood, Emi; Schwendeman, Rachel; Shields, Jerry A.

doi:10.1097/icu.0000000000000091

Cited by 144 publications

(79 citation statements)

References 64 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intra-arterial chemotherapy (IAC) has substantially improved globe salvage rates for eyes with moderate to advanced disease [1-6]. In a previous report of our 5-year experience with IAC by the International Classification of Retinoblastoma (ICRB) group, we found globe salvage rates of 100% for group B and C eyes, 94% for group D eyes, and 36% for group E eyes [2].…”

Section: Introductionmentioning

confidence: 99%

“…In a previous report of our 5-year experience with IAC by the International Classification of Retinoblastoma (ICRB) group, we found globe salvage rates of 100% for group B and C eyes, 94% for group D eyes, and 36% for group E eyes [2]. While IAC is effective for the majority of group B, C, and D eyes, the efficacy of IAC alone is limited in eyes with extensive vitreous seeds [1-6]. …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Primary Intra-Arterial Chemotherapy for Retinoblastoma in the Intravitreal Chemotherapy Era: Five Years of Experience

et al. 2018

View full text Add to dashboard Cite

Purpose: To report our 5-year experience with intra-arterial chemotherapy (IAC) in the intravitreal chemotherapy (IvitC) era. Methods: Retrospective review of retinoblastoma treated with primary unilateral IAC in the IvitC era (2012–2017). Results: There were 34 eyes treated with IAC alone versus 20 eyes treated with IAC plus IvitC for vitreous seeds. IAC (IAC alone vs. IAC plus IvitC) consisted of melphalan (41 vs. 10%) or melphalan plus topotecan (59 vs. 90%, p = 0.03). IvitC consisted of melphalan (60%) or melphalan plus topotecan (40%). Tumor control and globe salvage were achieved in 100% of group B and C eyes without IvitC. Despite more extensive vitreous seeds in the IvitC group (p < 0.01), comparison of IAC alone versus IAC plus IvitC revealed no difference in tumor control for group D (88 vs. 69%, p = 0.36) or group E (67 vs. 100%, p = 0.25) and no difference in globe salvage for group D (88 vs. 69%, p = 0.36) or group E (58 vs. 57%, p = 0.39). Conclusions: IAC is effective as primary therapy for unilateral group B, C, D, and E retinoblastoma. IvitC is an important adjuvant therapy to achieve comparable globe salvage rates for group D and E eyes with persistent active vitreous seeds.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Primary Intra-Arterial Chemotherapy for Retinoblastoma in the Intravitreal Chemotherapy Era: Five Years of Experience

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Высокая актуальность изучения проблемы РБ в настоящий момент связана с необходимостью вне-дрения современных органосохраняющих методов ле-чения -интравитреальной или селективной интраар-териальной химиотерапии (ХТ), а в ряде случаев и системной высокодозной ПХТ [8,9].…”

unclassified

Organizational aspects of the treatment of retinoblastoma in children in the Russian Federation on the basis of survey of regional centers of pediatric hematology-oncology

Ивановна¹,

Шаманская²,

Качанов³

et al. 2016

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

“…A total of 40% of the retinoblastomas may occur bilaterally and are supposed to arise out of a somatic mutation of the RB1 gene. In 30% of the cases, a spontaneous germline mutation may lead to the defect of the RB1 gene, whereas in about 10% of the cases, the RB1 gene defect is inherited by a parent [2]. The latter describes an autosomal dominant genetic pattern with incomplete penetrance.…”

Section: Introductionmentioning

confidence: 99%

“…To treat the cancer and safe the life of a child, enucleation may be required in some circumstances. Focal treatment with cryo- and photocoagulation or systemic treatment such as chemotherapy and radiation sometimes allow preservation of the eye in small and early cancers [2]. Recently, intra-arterial chemotherapy has allowed enhanced treatment outcomes with a higher percentage of eye-sparing cases.…”

Section: Introductionmentioning

confidence: 99%

Clinical Presentation and Genetic Paradigm of Diffuse Infiltrating Retinoblastoma: A Review

2015

View full text Add to dashboard Cite

Retinoblastoma is the most common childhood cancer. Thanks to modern technology and good medical access, mortality in Europe has decreased to about 5%. Diffuse infiltrating retinoblastoma is a very rare subtype of this neoplasm and is characterized by its atypical growth pattern. Diffuse infiltrating retinoblastoma may mimic other more innocuous diseases and may therefore be misdiagnosed. The purpose of this paper was to provide a short review of the main symptoms of diffuse infiltrating retinoblastoma presenting to the ophthalmologist and give a comparison to typical retinoblastoma. The second purpose was to set up a discussion of the genetic paradigm of diffuse infiltrating retinoblastoma. It has often been described to occur sporadically; however, in the last years, it has been shown that it might be heritable. A literature search concerning diffuse infiltrating retinoblastoma considering English, German and Spanish cases and case series identified 77 patients. Moreover, an overview of general data, main symptoms, clinical findings and initial working diagnoses or referral diagnoses is given. Males were significantly more often affected than females. Diffuse infiltrating retinoblastoma can be heritable. Genetic analysis should be offered to the patient and relatives. Interdisciplinary medical follow-up care is needed to detect associated cancers.

show abstract

Targeted retinoblastoma management

Abstract: Chemotherapy is effective for retinoblastoma and the targeted treatment route depends on the clinical features and anticipated outcomes.

Cited by 144 publications

References 64 publications

Primary Intra-Arterial Chemotherapy for Retinoblastoma in the Intravitreal Chemotherapy Era: Five Years of Experience

Primary Intra-Arterial Chemotherapy for Retinoblastoma in the Intravitreal Chemotherapy Era: Five Years of Experience

Organizational aspects of the treatment of retinoblastoma in children in the Russian Federation on the basis of survey of regional centers of pediatric hematology-oncology

Clinical Presentation and Genetic Paradigm of Diffuse Infiltrating Retinoblastoma: A Review

Contact Info

Product

Resources

About